154 related articles for article (PubMed ID: 37717564)
1. Immunohistochemistry, Molecular Biology, and Clinical Scoring for the Detection of Muir-Torre Syndrome in Cutaneous Sebaceous Tumors: Which Strategy?
Sinson H; Karayan-Tapon L; Godet J; Rivet P; Alleyrat C; Battistella M; Pierron H; Morel F; Lecron JC; Favot L; Frouin E
Dermatology; 2023; 239(6):889-897. PubMed ID: 37717564
[TBL] [Abstract][Full Text] [Related]
2. Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms.
Roberts ME; Riegert-Johnson DL; Thomas BC; Thomas CS; Heckman MG; Krishna M; DiCaudo DJ; Bridges AG; Hunt KS; Rumilla KM; Cappel MA
J Genet Couns; 2013 Jun; 22(3):393-405. PubMed ID: 23212176
[TBL] [Abstract][Full Text] [Related]
3. An Intrapatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome.
Nguyen CV; Gaddis KJ; Stephens MR; Seykora JT; Chu EY
JAMA Dermatol; 2020 Jun; 156(6):676-680. PubMed ID: 32267475
[TBL] [Abstract][Full Text] [Related]
4. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.
Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP
J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607
[TBL] [Abstract][Full Text] [Related]
5. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
Jessup CJ; Redston M; Tilton E; Reimann JD
Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm.
Abbas O; Mahalingam M
J Cutan Pathol; 2009 Jun; 36(6):613-9. PubMed ID: 19515040
[TBL] [Abstract][Full Text] [Related]
7. Sebaceous Neoplasms.
Flux K
Surg Pathol Clin; 2017 Jun; 10(2):367-382. PubMed ID: 28477886
[TBL] [Abstract][Full Text] [Related]
8. Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy.
Ponti G; Meschieri A; Pollio A; Ruini C; Manfredini M; Longo C; Mandel VD; Ciardo S; Tomasi A; Giannetti L; Pellacani G
J Oral Pathol Med; 2015 Aug; 44(7):552-7. PubMed ID: 25213213
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population.
Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R
Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614
[TBL] [Abstract][Full Text] [Related]
10. The M2 macrophages infiltration of sebaceous tumors is linked to the aggressiveness of tumors but not to the mismatch repair pathway.
Frouin E; Alleyrat C; Godet J; Karayan-Tapon L; Sinson H; Morel F; Lecron JC; Favot L
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6445-6454. PubMed ID: 36763173
[TBL] [Abstract][Full Text] [Related]
11. Sebaceous carcinoma epidemiology, associated malignancies and Lynch/Muir-Torre syndrome screening in England from 2008 to 2018.
Cook S; Pethick J; Kibbi N; Hollestein L; Lavelle K; de Vere Hunt I; Turnbull C; Rous B; Husain A; Burn J; Lüchtenborg M; Santaniello F; McRonald F; Hardy S; Linos E; Venables Z; Rajan N
J Am Acad Dermatol; 2023 Dec; 89(6):1129-1135. PubMed ID: 37031776
[TBL] [Abstract][Full Text] [Related]
12. Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm.
Everett JN; Raymond VM; Dandapani M; Marvin M; Kohlmann W; Chittenden A; Koeppe E; Gustafson SL; Else T; Fullen DR; Johnson TM; Syngal S; Gruber SB; Stoffel EM
JAMA Dermatol; 2014 Dec; 150(12):1315-21. PubMed ID: 25006859
[TBL] [Abstract][Full Text] [Related]
13. Role of microsatellite instability, immunohistochemistry and mismatch repair germline aberrations in immunosuppressed transplant patients: a phenocopy dilemma in Muir-Torre syndrome.
Ponti G; Manfredini M; Pellacani G; Tomasi A
Clin Chem Lab Med; 2016 Nov; 54(11):1725-1731. PubMed ID: 27016151
[TBL] [Abstract][Full Text] [Related]
14. [Muir-Torre syndrome and Turcot syndrome].
Velter C; Caussade P; Fricker JP; Cribier B
Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
[TBL] [Abstract][Full Text] [Related]
15. Considerations on the performance of immunohistochemistry for mismatch repair gene proteins in cases of sebaceous neoplasms and keratoacanthomas with reference to Muir-Torre syndrome.
Fernandez-Flores A
Am J Dermatopathol; 2012 Jun; 34(4):416-22. PubMed ID: 22123265
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinicopathologic features, survival, and demographics in sebaceous carcinoma patients with and without Muir-Torre syndrome.
Maloney NJ; Zacher NC; Hirotsu KE; Rajan N; Aasi SZ; Kibbi N
J Am Acad Dermatol; 2023 Aug; 89(2):269-273. PubMed ID: 37003478
[TBL] [Abstract][Full Text] [Related]
17. Universal immunohistochemical screening of sebaceous neoplasms for Muir-Torre syndrome: Putting the cart before the horse?
Kim RH; Nagler AR; Meehan SA
J Am Acad Dermatol; 2016 Nov; 75(5):1078-1079. PubMed ID: 27745640
[No Abstract] [Full Text] [Related]
18. Somatic MMR gene mutations as a cause for MSI-H sebaceous neoplasms in Muir-Torre syndrome-like patients.
Joly MO; Attignon V; Saurin JC; Desseigne F; Leroux D; Martin-Denavit T; Giraud S; Bonnet-Dupeyron MN; Faivre L; Auclair J; Grand-Masson C; Audoynaud C; Wang Q
Hum Mutat; 2015 Mar; 36(3):292-5. PubMed ID: 25504677
[TBL] [Abstract][Full Text] [Related]
19. [Muir-Torre syndrome--a phenotypic variant of Lynch syndrome].
Kacerovská D; Kazakov DV; Cerná K; Hadravský L; Michal M; Dostál J; Skálová A; Michal M
Cesk Patol; 2010 Oct; 46(4):86-94. PubMed ID: 21313735
[TBL] [Abstract][Full Text] [Related]
20. Muir-Torre syndrome: case report and review of the literature.
Ang JM; Alai NN; Ritter KR; Machtinger LA
Cutis; 2011 Mar; 87(3):125-8. PubMed ID: 21488569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
